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ABSTRACT
The mechanisms by which hepatitis B virus (HBV) establishes and maintains chronic hepatitis B infection (CHB) are poorly de-
fined. Innate immune responses play an important role in reducing HBV replication and pathogenesis. HBV has developed nu-
merous mechanisms to escape these responses, including the production of the secreted hepatitis B e antigen (HBeAg), which
has been shown to regulate antiviral toll-like receptor (TLR) and interleukin-1 (IL-1) signaling. IL-18 is a related cytokine that
inhibits HBV replication in hepatoma cell lines and in the liver through the induction of gamma interferon (IFN-) by NK cells
and T cells. We hypothesized that HBV or HBV proteins inhibit IFN- expression by NK cells as an accessory immunomodula-
tory function. We show that HBeAg protein inhibits the NF-B pathway and thereby downregulates NK cell IFN- expression.
Additionally, IFN- expression was significantly inhibited by exposure to serum from individuals with HBeAg-positive but not
HBeAg-negative chronic HBV infection. Further, we show that the HBeAg protein suppresses IL-18-mediated NF-B signaling
in NK and hepatoma cells via modulation of the NF-B pathway. Together, these findings show that the HBeAg inhibits IL-18
signaling and IFN- expression, which may play an important role in the establishment and/or maintenance of persistent HBV
infection.
IMPORTANCE
It is becoming increasingly apparent that NK cells play a role in the establishment and/or maintenance of chronic hepatitis B
infection. The secreted HBeAg is an important regulator of innate and adaptive immune responses. We now show that the
HBeAg downregulates NK cell-mediated IFN- production and IL-18 signaling, which may contribute to the establishment of
infection and/or viral persistence. Our findings build on previous studies showing that the HBeAg also suppresses the TLR and
IL-1 signaling pathways, suggesting that this viral protein is a key regulator of antiviral innate immune responses.
The mechanisms by which hepatitis B virus (HBV) establishesand maintains persistent infection are not fully understood. It
has become increasingly apparent that innate immune response
via the effector functions of a range of cell types, including Kupffer
cells, natural killer (NK) cells, and hepatocytes, play an important
role in controlling HBV infection (1–3). Our group has previously
shown that stimulation of the interleukin-1 (IL-1) and toll-like
receptor 2 (TLR2) signaling pathways inhibits HBV replication in
vitro (4). In turn, we and others have shown that the hepatitis B e
antigen (HBeAg; p17) downregulates antiviral TLR2- and IL-1-
mediated responses (5–7). HBeAg is secreted as a nonparticulate
form of the hepatitis B virus (HBV) nucleocapsid protein (hepa-
titis B core antigen [HBcAg]; p21), which is processed from larger
precore polyproteins (p25 and p22) (8). Although not required for
HBV replication, the precore protein and HBeAg are critical for
the establishment of persistent infection. The HBV precore pro-
tein and HBeAg are important regulators of innate and adaptive
immune responses that contribute to the establishment and/or
maintenance of persistent infection.
IL-18 is a proinflammatory cytokine synthesized and secreted
by mononuclear cells, including Kupffer cells. In the presence of
the necessary costimulatory ligands, such as IL-12 (9), IL-18 stim-
ulates IFN- production by NK cells, T cells, dendritic cells (DCs),
and B cells. IL-18 signaling is activated following the interaction of
two receptors: the alpha-receptor, IL-18R1, and the beta-receptor,
AcPL, both of which dimerize following ligand binding to the
alpha component, initiating signal transduction by AcPL (10).
Murine studies have shown that IL-18 (11) inhibits HBV replica-
tion through induction of IFN- (12, 13), which directly inhibits
the HBV life cycle at the pre- and posttranslational level. In vitro
studies have recently shown that, similar to IL-1 (4), overexpres-
sion of IL-18 inhibits HBV replication in a hepatoma cell line (14),
although the mechanism for this inhibition is unclear, as hepato-
cytes do not produce IFN-.
NK cells are lymphocytes that eliminate virus-infected cells by
both direct cytolysis and the production of several antiviral cyto-
kines, including IFN-. HBV infection stimulates NK cells, most
likely via the activation of DCs and macrophages that produce
IL-12, IL-18, and chemokines, including CXCR3 (15). NK cells
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are present in the liver and the periphery, with the majority of
intrahepatic NK cells having a CD56bright phenotype, whereas
CD56dim NK cells are found predominantly in the periphery. It is
generally believed that CD56dim NK cells produce less IFN- and
are more cytotoxic than CD56bright cells. Despite this, a recent
study has shown that a large proportion of the IFN--producing
NK cells in the setting of chronic hepatitis B (CHB) belong to the
CD56dim subset (16). Indeed, it has been shown that IFN- ex-
pression by NK cells is lower in CHB patients than in uninfected
controls, and IFN- expression is restored by antiviral therapy
that reduces HBV replication (16). This implicates a role for either
HBV itself or cellular factors upregulated by HBV replication in
impairing IFN- production by NK cells and contributing to viral
persistence. This reduction in IFN- production may be due in
part to the upregulation of immunosuppressive cytokines, such as
IL-10, which suppress IFN- expression by NK cells (18). The
blocking of these cytokines restores the capacity of NK cells in
both the liver and periphery to produce IFN- (18). Interestingly,
Schlaak and colleagues have shown that IFN- responses were
lower following stimulation of peripheral blood mononuclear
cells (PBMCs) from chronically infected HBeAg-positive patients
than from HBeAg-negative patients (19). This suggests that mol-
ecules upregulated during HBeAg-positive CHB or the HBeAg
itself contribute to IFN- suppression.
Therefore, we have investigated whether the HBeAg protein
impairs IL-18-mediated IFN- expression by NK cells. We show
that IFN- production by NK cells within the periphery of healthy
subjects is downregulated following treatment with HBeAg pro-
tein but not the closely related HBV core protein. Additionally, we
found that IFN- production by NK cells was significantly inhib-
ited by exposure to serum from individuals with HBeAg-positive
but not HBeAg-negative chronic HBV infection. We further in-
vestigated whether the HBeAg and related proteins altered IL-18
signaling itself, using in vitro NK and hepatoma cell culture mod-
els. We show that HBeAg precursor proteins suppress IL-18-me-
diated NF-B signaling in NK92 and Huh7 hepatoma cells,
whereas the related core protein did not. Together, these findings
show that the HBV precore protein and HBeAg regulate IFN-
production and IL-18 signaling and suggest that this regulation
plays a role in the establishment and/or maintenance of persistent
HBV infection.
MATERIALS AND METHODS
Whole-blood assay for in vitro analysis of IL-18-mediated IFN- ex-
pression. Whole-blood samples (100 l) from healthy control volunteers
were incubated with 10 ng/ml of IL-18 (MBL, Nagoya, Japan) and 10
ng/ml IL-12 (MBL, Nagoya, Japan) in the presence of 100 l serum from
patients with CHB or chronic HCV infection, a healthy control serum, or
RPMI 1640 (control) (Life Technologies, CA) at a final dilution of 1:2
unless otherwise stated. All samples were incubated in a 96-well plate for
24 h at 37°C, 5% CO2, similar to previously described methods (16). After
18 h of stimulation, 10 g/ml of brefeldin A (Sigma-Aldrich, Sydney,
Australia) was added to each well and incubated for the remaining 6 h at
37°C, 5% CO2. Following this, samples were incubated with Live/Dead
fixable aqua dead cell stain (Life Technologies) at a 1/200 dilution for 30
min at room temperature in the dark. Subsequently, samples were further
incubated with anti-CD3 peridinin chlorophyll protein (PerCP) (SP34-2;
Becton, Dickinson [BD], North Ryde, Australia), anti-CD14 phycoeryth-
rin (PE)-Cy7 (M5E2; BD, North Ryde, Australia), anti-CD56 allophyco-
cyanin (APC) (B159; BD, North Ryde, Australia), and anti-IL-18R1-flu-
orescein isothiocyanate (FITC) (Ab93546; Abcam, Sapphire Bioscience,
Waterloo, Australia) for an additional 30 min at room temperature in the
dark. Red blood cells then were lysed using OptiLyse C (Beckman Coulter,
Gladesville, Australia) at room temperature for 10 min and washed. White
blood cells were permeabilized using 1 BD fluorescence-activated cell
sorting (FACS) permeabilizing solution 2 (BD, North Ryde, Australia) for
10 min and washed. Finally, samples were incubated at room temperature
for 1 h with anti-IFN--AF700 (B27; BD, North Ryde, Australia) in the
dark. Cells then were washed and fixed with 1% paraformaldehyde (Sig-
ma-Aldrich, Sydney, Australia). Acquisition was performed on an LSRII
flow cytometer (BD) with 106 lymphocyte events collected and analyzed
using FlowJo, version 9.2 (TreeStar, Ashland, Oregon). IFN- production
in NK CD56bright and NK CD56dim cells was measured as (i) the percent-
age of NK cells expressing IFN- and (ii) IFN- mean fluorescence inten-
sity (MFI). The specificity of the assay for IL-12/IL-18-driven IFN- pro-
duction was assessed by blocking with antibodies to IL-18R1 (ab93546;
Abcam, Sapphire Bioscience, Waterloo, Australia) and AcPL (ab47269;
Abcam, Sapphire Bioscience, Waterloo, Australia) receptors and/or stim-
ulation with 10 ng/ml lipopolysaccharide (LPS; Sigma-Aldrich, Sydney,
Australia).
HBV proteins. One hundred l of whole blood from uninfected con-
trols was stimulated with 100 l of supernatant obtained from cells stably
transformed with genes expressing the HBV HBeAg (p17) or core protein
(p21) or untransformed controls (referred to as HBeAg, core, or control
conditioned medium, respectively) (6, 20). The conditioned medium was
collected 9 days after seeding cells, and the HBeAg titer was determined by
the Abbot Architect procedure (21) and typically measured 600 Paul Er-
lich (PE) IU/ml. Since the conditioned medium was diluted 1:1 with se-
rum in our assay, each well typically contained 300 PE IU/ml of HBeAg.
This is biologically relevant, with clinical studies showing this to be within
the second quartile of HBeAg titers (21). Core protein expression in the
HBcAg media was confirmed by Western blotting (not shown) and con-
tained no HBeAg (20). Whole blood also was stimulated with HBV virion-
positive conditioned medium from AD38 cells, which are HepG2-derived
hepatoblastoma cells stably transformed with HBeAg-positive infectious
cDNA (22). The supernatant from these cells had an HBV viral load of
3.2  107 IU/ml and also was weakly HBeAg positive, with HBeAg levels
typically registering 20 PE IU/ml. The effect of each of these conditioned
media on IFN- signaling was assessed by flow cytometry as described
above.
NK cell culture assay for analysis of IL-18-mediated IFN- expres-
sion. The assay described above also was performed using NK-92 cells
(ATCC CRL-2407), which are an IL-2-dependent PBMC-derived NK cell
line. NK-92 cells were grown as recommended by the ATCC in alpha-
minimal essential medium (Sigma) supplemented with 10% fetal calf se-
rum (FCS; HyClone), 10% horse serum (Invitrogen), and 50 IU/ml IL-2
(Peprotech). Cells were seeded into 96-well plates, and 24 h postseeding
they were treated with 100 l HBeAg, core, or control conditioned me-
dium. Cells were harvested 24 h posttreatment, and the effect of each of
these conditioned media on IFN- signaling was assessed by flow cytom-
etry as described above.
Patient samples. Peripheral blood samples were obtained from 13
patients with chronic HBeAg-positive hepatitis B, 20 patients with
chronic HBeAg-negative hepatitis, 10 patients with chronic hepatitis C
virus (HCV) infection (HCV RNA, 3.2  106  2.4  106 IU/ml), and 12
uninfected controls. All patients were treatment naive, HIV negative, and
(with the exception of the HCV controls) HCV negative. HBV viral load
was measured by the Versant HBV DNA 3.0 assay (linear range, 2  103 to
1  108 IU/ml; Bayer, Tarrytown, NY), and the HBV genotype and HBeAg
and HBsAg levels in serum were determined and measured as described
previously (21). The 13 HBeAg-positive subjects had a mean HBV viral
load of 1.47  109 IU/ml and serum HBeAg level of 2,254 PE IU/ml. For
the 20 HBeAg-negative subjects, the mean HBV viral load was 2.2  103
IU/ml (Table 1).
All studies were approved by the St. Vincent’s Hospital Melbourne
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human research ethics committee (HREC), HREC numbers 093/04, 005/
11, 045/11, and 043/11.
Cytokine arrays on serum. The levels of IL-10 (no. 561514), IFN-
(561515), and IL-12p70 (561518) in serum were determined using human
enhanced-sensitivity flex set assays (BD, Sydney, Australia). These assays
detect specific cytokines in the range of 274 to 200,000 fg/ml. Briefly, 50 l
of serum was mixed with 20 l of mixed capture beads, incubated for 2 h,
and then washed and treated with enhanced-sensitivity detection reagent
(no. 561521) according to the manufacturer’s instructions. Samples were
acquired on a BD FACSCanto II cytometer.
Plasmids and transfection for in vitro analysis of IL-18-mediated
NF-B signaling. Expression of mammalian expression plasmids encod-
ing variants of the HBV precore gene (p25 and p22) or core gene (p21) was
confirmed by Western blotting and quantified by the Abbot Architect
procedure (21). The replication and protein expression of greater-than-
genome-length (1.3 mer) infectious cDNAs encoding wild-type (wt) HBV
or the G1896A precore stop codon mutation have been described previ-
ously by our group (4, 23).
NF-B luciferase reporter assay. The effect of the HBV precore pro-
tein on IL-18-mediated cell signaling in Huh7 cells was analyzed using a
previously described luciferase reporter assay (24) adapted for Huh7 cells.
It was not possible to perform these studies in NK-92 cells, as they were
not permissive to transfection with the appropriate expression constructs
(not shown). Briefly, Huh7 cells were seeded into 24-well plates and trans-
fected (Fugene, Roche, IN) 24 h postseeding with 100 ng pAcPL and 100
ng of HBV HBeAg precursor construct p25, p22, or p21 (core) or plasmids
encoding infectious wt HBV or G1896A precore mutant HBV cDNA.
Cells also were cotransfected with 188 ng of pNF-B and 62 ng of TK
renilla plasmid (transfection control). A cytomegalovirus (CMV)-driven
empty vector plasmid was included to ensure the same amount of DNA
was added per transfection. Cells were stimulated with 60 ng/ml IL-18
(MBL) 24 h posttransfection and harvested in passive lysis buffer (Pro-
mega, Sydney, Australia). The level of NF-B and TK renilla-driven lucif-
erase expression was measured using an Optima luminometer (BMG
Labtech, Mornington, Australia) according to the manufacturer’s instruc-
tions.
PhosFlow assay. The ability of the HBeAg to suppress IL-18/IL-12-
mediated NF-B signaling was investigated using a PhosFlow assay. Cells
were seeded into 96-well plates (1 million cells per well), and 24 h post-
seeding they were treated with 100 l HBeAg, core, or control conditioned
medium. Twenty hours later cells were stimulated for 15 min with 20
ng/ml IL-12/IL-18 and then immediately fixed by the addition of an equal
volume of prewarmed (to room temperature) PhosFlow fix buffer I (BD)
to the cell suspension according to the manufacturer’s guidelines. Cells
were washed twice with BD PhosFlow perm/wash buffer I and were added
to tubes containing PE mouse anti-NF-B p65 (pS529) (no. 558423) or
appropriate isotype control antibodies and incubated for 30 min at room
temperature in the dark. Cells were washed with BD PhosFlow perm/wash
buffer I and resuspended for immediate flow-cytometric analysis with the
BD FACSCanto II cytometer.
Statistical analyses. To determine whether any virological or patient
parameters shown in Table 1 were associated with IFN- expression, anal-
ysis was performed using GraphPad version 5.03 for Windows (GraphPad
Software Inc., La Jolla, CA). Data initially were assessed for normality and
log transformed where necessary. Normally distributed, continuous data
were reported as means  standard errors of means. Nonparametric data
were reported as median (range) values. Categorical data were reported as
numbers (percentages). Exploratory analysis was conducted using stu-
dent t tests, chi-square tests for equal proportion, or nonparametric tests
where appropriate. Multivariate analysis for continuous, normally dis-
tributed variables was conducted using generalized linear modeling, and
for binomially distributed variables it was performed using multiple lo-
gistic regressions. The log-rank test was used for comparison between
groups. In all cases a two-sided P value of less than or equal to 0.05 was
considered statistically significant. Data shown in Fig. 3 and 4 (and Fig. S1
in the supplemental material) were analyzed using SPSS software, version
18 (Chicago, IL, USA). Mann-Whitney U tests were used to analyze data
shown in Fig. 3A. A two-way repeated-measures analysis of variance
(ANOVA) was used to analyze data shown in Fig. 3B. Data shown in Fig.
4 and 5 were analyzed using a Spearman test and a Friedman test, followed
by Wilcoxon signed-rank tests with Bonferroni adjustment to the alpha
values. In these analyses, 2 tests were used, leading to a new alpha level of
0.025. For cytokine analysis, results were analyzed using Kruskal-Wallis
equality-of-proportions rank tests and two-sample Wilcoxon rank-sum
(Mann-Whitney) tests. For PhosFlow analysis and results presented in
Fig. 5, significance was determined using Student’s t test assuming un-
equal variance (GraphPad Prism 5).
RESULTS
Interrogation of IL-18-mediated IFN- expression by NK cells.
We measured IL-18-mediated IFN- production by NK cells us-
ing a previously described whole-blood assay (16). Briefly, healthy
donor whole blood was stimulated with IL-18 and IL-12 to stim-
ulate robust IFN- expression from NK cells (Fig. 1A and B). This
resulted in a mean of 12.79% (9.95%) of CD14 CD3 CD56	
NK cells expressing IFN- in the presence of healthy donor serum.
The specificity of IL-18-mediated IFN- expression was demon-
strated by blockade of the IL-18 receptor using antibodies to either
component of the receptor (IL-18R1 or AcPL), which effectively
inhibited NK cell IFN- expression (Fig. 1B).
HBeAg protein downregulates IFN- production by NK
cells. The HBeAg previously has been shown to downregulate
innate immune signaling in a range of cell types (6, 7, 25). To
determine whether the HBeAg specifically downregulated IL-18-
mediated IFN- expression in NK cells, we stimulated whole
blood from 10 healthy control blood donors with IL-18 and IL-12
in the presence of control, precore, core, or whole virus condi-
tioned media and measured the frequency of NK cells expressing
IFN-. IL-18 stimulation of whole blood in conjunction with
HBeAg protein demonstrated significant downregulation of
IFN- expression in NK cells compared to control media with no
TABLE 1 Clinical demographics of HBV-infected patients who supplied the serum used in the whole-blood assay
Parameter
Value according to HBeAg status
P valueaPositive (n 
 13) Negative (n 
 20)
Age (yr) 29  6 44  14 0.011
Male gender (%) 54 65 NS
HBV genotype (proportion) B (58%), C (25%), D (8%) B (69%), C (25%), D (6%) NS
HBV DNA (IU/ml) 1.47  109  2.7  109 2.2  106  4.9  106 NS
HBeAg (PE IU/ml) 2,254  103  3.6  103 0 0.011
HBsAg (IU/liter) 2.0  104  2.6  104 5.9  103  6.9  103 NS
ALT (IU/liter) 117  76 68  59 0.032
a NS, not significant.
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HBeAg (Fig. 2A [P 
 0.005] and 3B [P 
 0.022]). Treatment with
core or with whole HBV-positive conditioned media (whole HBV,
HBsAg positive, and weakly HBeAg positive) did not alter IFN-
production by NK cells (Fig. 2A and B) in whole blood. Further
analysis of NK cell phenotypes showed IFN- expression was
higher in CD56bright cells than in CD56dim cells (Fig. 2C and D).
Despite this, the HBeAg-containing conditioned media reduced
IFN- expression similarly in both NK cell subtypes (Fig. 2C and
D). To confirm this was a direct effect on NK cells, NK-92 cells
were stimulated with IL-18, and IFN- production by NK cells
was measured in the presence of condition media. To assess
whether IFN- expression by NK cells was affected by stimuli
other than IL-12/IL-18, we stimulated whole blood with LPS. LPS
treatment of cells results in IFN- expression both directly via
stimulation of TLR4 and indirectly through activation of the in-
flammasome, producing IL-18, which results in IFN- (26). Fol-
lowing treatment with HBeAg-containing media or HBeAg-neg-
ative media, we obtained results almost identical to those obtained
following direct IL-12/IL-18 stimulation, with a significant reduc-
tion in NK cell-driven IFN- expression, irrespective of whether
we examined the percentage of cells expressing IFN- (P 
 0.005)
(Fig. 2E) or mean fluorescence (P 
 0.005) (Fig. 2F). Blocking
experiments showed that anti-IL-18 receptor antibodies pre-
vented IFN- expression by NK cells, showing that LPS-driven
upregulation of IFN- most likely was mediated via activation of
IL-12/IL-18 in cells such as DCs and not by direct activation of
IFN- via the LPS receptor TLR4 in NK cells (Fig. 2G). As ex-
pected, the HBeAg also reduced IFN- expression in NK92 cells
(Fig. 2H). Interestingly, in these cells we also observed a small but
nonetheless statistically significant reduction in IFN- expression
in cells exposed to core-expressing media compared to control
media. To confirm that inhibition of IFN- was dose dependent
on HBeAg protein, we determined the amount of HBeAg protein
required to suppress IFN- expression following IL-12/IL-18
stimulation of whole blood. We observed that 300 PE IU/ml
HBeAg suppressed NK cell IFN-, but this effect was ameliorated
when HBeAg conditioned medium was diluted to 50 PE IU/ml
(Fig. 2I). This indicates that HBeAg protein inhibits IL-18-medi-
ated IFN- production by NK cells with a dose-dependent mech-
anism.
We were interested next to determine a possible mechanism
for this downregulation. We stimulated NK-92 cells with IL-18/
IL-12 and measured NF-B phosphorylation by flow cytometry.
Treatment of NK cells with HBeAg conditioned medium signifi-
cantly downregulated NF-B phosphorylation compared to core
or control conditioned medium (Fig. 2J), suggesting that HBeAg-
mediated suppression of IL-12/IL-18 signaling in NK-92 cells is
mediated through the NF-B signaling pathway.
Serum from HBeAg-positive individuals downregulated IL-
18-mediated IFN- production by NK cells. Since the HBeAg
FIG 1 IL-18/IL-12 stimulation of NK cells in whole blood. (A) Intracellular IFN- expression by NK cells analyzed by gating on viable CD14 CD3 CD56	
lymphocytes. The first panel shows cells sorted into lymphocytes based on forward (FSC-A, x axis) and side scatter (SSC-A, y axis). The second panel shows the
NK cell population analyzed. (B) Addition of either anti-IL-18R1 or anti-AcPL antibody prior to stimulation significantly reduced IFN- production.
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FIG 2 HBeAg-specific inhibition of IFN- production by NK cells following stimulation with IL-18/IL-12. Whole blood (A to D) from 10 uninfected control
donors or NK92 cells (H) was incubated with IL-18/IL-12 (A and B) or LPS (E and F) in the presence of conditioned media containing either HBeAg, core antigen,
purified HBsAg/virions (derived from AD38 cells), or control media. (G) LPS-mediated IFN- expression was blocked by treatment with the IL-18R1 antibody.
For whole-blood assays, the percentage of cells expressing IFN- is shown in panels A, C, D, E, and G, and the mean fluorescence intensity (MFI) of IFN--
producing cells is shown in panels B and F. The line on each graph depicts the median for each of three independent experiments. (I) IFN- expression in whole
blood from one uninfected control donor incubated with IL-18/IL-12 in the presence of conditioned media containing serial dilutions of HBeAg, core antigen,
or control media. Suppression of IFN- expression was dose dependent, with no significant difference from core or control media when HBeAg levels were 50
PE IU/ml or less. The line on each data set depicts the median. (J) Differences in the percentage of phosphorylated NF-B-positive NK92 cells observed following
IL-18/IL-12 stimulation and exposure to conditioned media expressing the HBeAg, core protein, or control.
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protein downregulated IFN- expression in NK cells, we next
were interested in determining whether endogenous HBeAg in
serum from HBV-infected individuals similarly modulated IFN-
expression in blood NK cells. We stimulated whole blood with
exogenous IL-18 and IL-12 and measured NK cell IFN- expres-
sion in the presence of plasma treated with serum from HBeAg-
positive and HBeAg-negative individuals. To ensure that the
reduction in NK cell IFN- expression was due specifically to
HBV-related factors and not to other factors present in serum
resulting from chronic viral infection of the liver, we included
serum from HCV-infected individuals. IFN- production by NK
cells was significantly suppressed following treatment of whole
blood with serum from chronic HBV HBeAg-positive individuals
(range, 0 to 15%; median, 2.24%) (Fig. 3A [P 
 0.004] and B [P 

0.001]) relative to uninfected controls. Further, there was a signif-
icantly lower level of production of IFN- by NK cells following
treatment of whole blood with serum from HBeAg-positive indi-
viduals compared to HBeAg-negative individuals (P 
 0.02). Al-
though we observed a much greater range of IFN- responses
following treatment of whole blood with serum from HBeAg-
negative individuals (0 to 45%; median, 9.5%), overall IFN- ex-
pression in NK cells treated with this serum did not differ signifi-
cantly from that of uninfected controls (Fig. 3A and B). This effect
was observed in whole blood from multiple control donors (P 

0.0016) (Fig. 3C). There was no association between suppression
of IFN- expression and HBsAg levels or alanine aminotransfer-
ase (ALT) (Table 1). Results were similar irrespective of whether
we measured the percentage of NK cells expressing IFN- (Fig.
3A) or the mean fluorescence intensity of IFN- expression (Fig.
3B). Treatment with serum from HCV-infected individuals had
no effect on IFN- expression by NK cells (Fig. 3A and B). This
indicates that HBeAg protein in serum from infected individuals
suppresses IL-18-stimulated IFN- production by NK cells.
IL-10 cytokine levels did not differ in serum derived from
HBeAg-positive or HBeAg-negative individuals. One mecha-
nism by which HBeAg-positive HBV downregulates IFN- ex-
pression is via upregulation of immunosuppressive cytokines,
such as IL-10, which have been shown to suppress NK cell IFN-
expression (18). To determine if endogenous cytokines differed in
patient serum used to stimulate NK cells in the whole blood assay,
we measured cytokines using a highly sensitive flow cytometry
assay. IL-10 levels were significantly higher in HBV-infected pa-
tients than in HCV-infected individuals (P 
 0.02), which were
predominantly below the limit of detection of the assay. No dif-
ference was observed in IL-10 levels in serum from HBeAg-nega-
tive and HBeAg-positive patients (Fig. 4 and Table 1). IL-10 levels
in serum of uninfected control patients were highly variable, and
overall they did not differ from levels in HBV-infected individuals,
most likely due to the high standard deviations for this small sam-
ple size. We observed no difference in endogenous serum IL-
12p70 or IFN- levels between groups (not shown). Together,
these findings suggest that NK cell-mediated IFN- levels mea-
FIG 3 Whole blood from a single uninfected control donor was incubated
with either uninfected control serum (n 
 10), chronic HBeAg-positive serum
(n 
 10), chronic HBeAg-negative serum (n 
 20), or chronic HCV serum
(n 
 10) and stimulated with IL-18/IL-12. (A) Percentage of NK cells express-
ing IFN-. (B) Mean fluorescence intensity of IFN--producing NK cells. (C)
Whole blood from 4 different uninfected control donors was incubated with
either uninfected control serum (n 
 2) or HBeAg-positive HBV serum (n 

2). HBeAg-positive serum significantly reduced IFN- expression in NK cells
from all uninfected donors. The line on each graph depicts the median for each
of three independent experiments.
FIG 4 IL-10 levels in serum of patients used in the whole-blood assay, detected
using the enhanced-sensitivity BD array.
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sured using our whole-blood assay were not influenced by endog-
enous serum IL-10, IL-12p70, or IFN-.
In vitro hepatoma cell line model to study IL-18 signaling.
We were interested next to determine whether the HBeAg protein
also can downregulate IL-18-mediated NF-B signaling in hepa-
tocytes. We have previously used a luciferase reporter hepatocyte
cell culture model to interrogate NF-B signaling pathways stim-
ulated by the related cytokine IL-1 (7). These cells support pro-
ductive HBV replication, enabling interrogation of the effect of
whole virus or viral proteins on cell signaling, which is not possible
in NK cells. Indeed, NK-92 cells were recalcitrant to transfection
with all constructs tested (not shown).
Previous studies using gel shift assays have shown that the tran-
scription factor NF-B is upregulated following stimulation with
exogenous IL-18 (27). This is important, as although IL-18 signal-
ing does not induce IFN- expression in hepatocytes, the tran-
scription factor NF-B promotes expression of numerous antivi-
ral cytokines, including IFN-, IFN-, and tumor necrosis factor
(TNF). We have previously shown that the HBeAg precursor pro-
teins P25 and P22 suppress NF-B signaling in hepatocyte cell
lines following stimulation with the related cytokine IL-1. We
now show that the HBeAg precursor proteins similarly downregu-
late IL-18-mediated NF-B signaling in Huh7 cells (Fig. 5A). We
also showed that wild-type HBV expressing the HBeAg inhibited
IL-18-stimulated, NF-B-driven luciferase expression, whereas
the G1896A mutant HBV that does not express HBeAg precursor
proteins or HBeAg did not (Fig. 5A). In contrast, the HBV p21
core protein had no effect on NF-B-driven luciferase expression
despite high levels of protein expression (Fig. 5B).
DISCUSSION
The ability of HBeAg-positive HBV to establish a chronic persis-
tent infection suggests that HBeAg modulates immune responses
against HBV. Indeed, it is known that the HBeAg modulates adap-
tive immune responses to the viral nucleocapsid (28) and down-
regulates TLR and IL-1 signaling pathways (6, 7, 25). It is becom-
ing increasingly evident that NK cells play an important role in
controlling HBV infection (16, 18), particularly early in the infec-
tion cycle (29). We now show that the HBeAg can specifically
downregulate IL-18-stimulated IFN- expression by NK cells,
providing a possible mechanism by which HBV suppresses NK
cell-mediated antiviral activity. Studies using conditioned media
showed that the HBeAg downregulated IFN- expression by NK
cells compared to media expressing core protein or HBsAg, using
either whole-blood assays or a clonal NK cell line. In addition,
serum from subjects with HBeAg-positive CHB significantly
downregulated IFN- expression in NK cells derived from un-
infected control individuals compared to serum from HBeAg-
negative patients or uninfected controls. Although we also ob-
served an increase in IFN- expression following stimulation
with LPS, which was also downregulated by the HBeAg, this
increase most likely was due to indirect activation of IL-18 in
other cells in the periphery (30) rather than direct activation of
the LPS receptor TLR4. This was supported by our finding that
LPS-stimulated IFN- expression was specifically blocked by
antibodies to IL-18 receptors and the published observation
that human NK cells do not express TLR4 (31), the major re-
ceptor for the LPS ligand.
It is possible that other factors in addition to the HBeAg in
patient serum also contribute to our findings. It has been shown
recently that the immunosuppressive cytokine IL-10 is upregu-
lated during CHB and inhibits NK cell IFN- expression (18).
Although we identified higher levels of IL-10 in the serum of HBV-
infected patients than in HCV-infected patients, there was no sig-
nificant difference in IL-10 levels in the serum of HBeAg-positive
or HBeAg-negative patients used in our study. This suggests that
IL-10 levels in patient serum did not affect IL-18-mediated NK cell
IFN- expression in our whole-blood assay. We did not detect any
difference in endogenous serum IL-12 levels, a key costimulatory
molecule for IFN- expression, or IFN- itself (data not shown).
We cannot rule out that other cytokines or other factors contrib-
ute to the inhibition of IFN- expression by NK cells in the pres-
ence of HBV sera. Despite this, our findings that HBeAg in con-
ditioned medium suppressed IL-18-mediated IFN- expression
and NF-B signaling by NK cells suggests that the HBeAg in pos-
itive serum contributes to downregulation of IL-18-mediated NK
cell IFN- expression in the periphery.
It has been proposed that regulation of NK cell-mediated
IFN- expression plays an important role in the establishment of
acute infection rather than the maintenance of persistent infection
(29). This hypothesis is based largely on the finding that NK cell
activity is lower in patients with chronic HBV, due in part to the
upregulation of intracellular cytokines, including IL-10 (18). Oth-
ers have concluded differently, suggesting that defects in the
CD56dim subset in the periphery of patients with chronic HBV
FIG 5 Downregulation of IL-18-stimulated NF-B-driven luciferase expres-
sion in Huh7 cells. (A) Luciferase expression corrected to IL-18-stimulated
Huh7 cells transfected with empty vector following transfection of cells with
CMV-driven expression plasmids expressing the HBeAg precursor (p22 or
p25), the HBV core protein (p21), or infectious cDNAs encoding wt HBV or
G1896A precore mutant HBV. Samples statistically different from empty vec-
tor controls are indicated by an asterisk (P  0.05). (B) Relative protein ex-
pression of CMV-driven reporter plasmids in transfected Huh7 cells, as deter-
mined by quantitative serology (21).
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play a role in persistence (16). This is supported by the findings
that activation of CD56dim NK cells was restored following antivi-
ral treatment that decreased the level of serum HBV (16). Our
findings that the HBeAg downregulates NK cell-mediated IFN-
expression suggest that HBeAg contributes to the downregulation
of NK cells during the establishment and/or maintenance of in-
fection. However, a limitation of our study is that we are unable to
draw conclusions regarding a role for HBeAg-mediated regulation
of NK cell IFN- expression in the maintenance of persistent in-
fection, as we did not compare NK cell-mediated IFN- expres-
sion in cells obtained from our HBeAg-positive or -negative CHB
patients. If HBeAg-mediated downregulation of NK cells contrib-
utes to maintenance of persistence, we predict NK cell-mediated
IFN- expression to have been lower in our HBeAg-positive pa-
tients. It is also possible that suppression of IFN- expression by
the HBeAg plays a role in the establishment of persistent infection
rather than the maintenance of the persistent state.
We have shown that the HBeAg downregulates IL-18-medi-
ated signaling in NK cells and Huh7 hepatoma cells through mod-
ulation of NF-B signaling. Although HBV does not infect NK
cells, the HBeAg is secreted into the peripheral blood. It is possible
that this effect is mediated by HBeAg interacting directly with
IL-18 receptors (IL-18R1 and/or AcPL) on the NK cell membrane.
Indeed, we showed that blocking these receptors abrogates IL-18-
stimulated IFN- expression in NK cells. The AcPL is a mem-
brane-spanning protein which binds to the alpha receptor IL-
18R1 to initiate signaling (10). Direct interaction with the
membrane-spanning AcPL provides one explanation for our find-
ings that the secreted HBeAg downregulates IL-18-mediated
IFN- expression in NK cells. It has recently been shown that the
HBeAg directly interacts with the related IL-1 receptor AcP (32),
and it remains to be determined if similar interactions are at play
in IL-18 signaling. We also show that the intracellular precursor
proteins p22 and p25 downregulate IL-18-mediated signaling in
hepatocytes by downregulating NF-B promoter activity in vitro.
This is similar to our previous findings in hepatocytes treated with
the related cytokine IL-1 (7) and shows that the HBeAg is a
powerful suppressor of IL-18 signaling across numerous cell
types.
Since IL-18-stimulated IFN- has direct antiviral effects
against HBV and activation of IL-18 signaling decreases HBV rep-
lication in hepatocytes (14), it is not surprising that HBV evolved
mechanisms to regulate IL-18 signaling and IFN- expression.
HBV utilizes numerous mechanisms to regulate other innate im-
munity signaling pathways, including HBeAg and precore pro-
tein-mediated regulation of TLR2 (5, 6) and IL-1 (7), with the
latter sharing a number of salient features with IL-18 signaling
(33). The mechanisms by which HBV establishes and maintains
chronic infection are still to be resolved. However, recent findings
that NK cell-driven IFN- responses are lower in CHB patients
with high HBV viral loads (16) and that upregulation of IL-1 or
the related IL-18 signaling inhibits HBV replication in hepatocytes
(4, 14) suggests that regulation of IL-18 is one mechanism by
which HBV facilitates persistence. This is further supported by
our findings that suppression of IFN- expression by NK cells is
directly mediated both by factors present in serum from HBeAg-
positive CHB patients and by the HBeAg protein itself. Modula-
tion of immune cells by the secreted HBeAg may be contributing
to the establishment of HBV infection and/or the maintenance of
HBV persistence in the setting of HBeAg-positive disease.
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